Voloridge Investment Management LLC Decreases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Voloridge Investment Management LLC cut its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 29.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,888 shares of the company's stock after selling 36,261 shares during the period. Voloridge Investment Management LLC owned about 0.16% of Stoke Therapeutics worth $958,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics in the 4th quarter valued at $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics in the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics during the fourth quarter valued at about $124,000. Tower Research Capital LLC TRC grew its stake in shares of Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after buying an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in shares of Stoke Therapeutics in the fourth quarter worth about $133,000.

Stoke Therapeutics Stock Down 1.2%

Shares of STOK traded down $0.12 during mid-day trading on Friday, hitting $9.61. 375,650 shares of the company's stock traded hands, compared to its average volume of 703,185. The firm has a market capitalization of $524.68 million, a P/E ratio of -4.58 and a beta of 1.20. The business's 50-day moving average price is $8.39 and its 200-day moving average price is $9.73. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on STOK. Chardan Capital restated a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. HC Wainwright lowered their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $23.20.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares of the company's stock, valued at $1,285,353.51. This represents a 6.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock worth $143,332 over the last 90 days. 11.30% of the stock is owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.